Abstract:Objective To evaluate the efficacy and safety of memantine in the treatment of patients with Alzheimer' s disease (AD).Methods This was a 16-week,multi-center,randomized,double blind, placebo-controlled clinical trial (Study 10116).A total of 258 AD patients (MMSE score 5—18) were randomized in a 1:1 ratio into either memantine 10—20 mg/day (MEM,n=128) or placebo (PBO,n= 130) group for 16 weeks.Efficacy was primarily assessed in terms of changes of severe impairment battery (SIB) score in patients from baseline up to SIB assessment in the 16th week (16-week completers set, CS16).While ehanges of MMSE,ADCS-ADL_(19),and NPI (neuropsychiatric inventory) were evaluated as secondary efficacy parameters on both CSI6 and full-analysis set (FAS).Safety was assessed by physical examination,lab assays,ECG,and adverse events.Results 236 subjeets (CS16:MEM n=117,PBO n=119) were eligible for the efficacy assessment.No statistically significant difference between the treatments was observed on the primary and seeondary efficacy analysis,although both treatment groups had a slight increase from baseline in SIB total score.Post hoe evaluation of the data identified two bias factors that had a significant impact on the results of the pre-protoeol specified primary and secondary analyses.In a re-analysis of the data (CS16_(modified),MEM n=94,PBO n=95) excluding patient data affeeted by these factors,memantine-treated patients showed a statistically significant improvement related to placebo in the 16th week on the SIB (MEM 2.2 vs PBO 0.3,P=0.04),MMSE (MEM 1.0 vs PBO 0.1,P=0.03),and ADL (MEM 0.1 vs PBO-1.6,P=0.02) scales,indicating that memantine improved the cognitive function of AD patients and stabilized the activity of daily life.Memantine was well tolerated with an adverse event profile similar to that of placebo.Conclusion This study provides further support for pre-existing data,showing that memantine is efficacious,safe,and well-tolerated in patients with moderate to severe AD.

Detection and analysis of signals of adverse events of memantine based on the US food and drug administration adverse event reporting system

P4‐305: Withdrawn

Identification of Adverse Drug Events in Chinese Clinical Narrative Text

Safety of Memantine in Combination with Potentially Interactive Drugs in the Real World: A Pharmacovigilance Study Using the Japanese Adverse Drug Event Report (JADER) Database

Mining and analysis of security alert signals of valbenazine based on the Food and Drug Administration Adverse Event Reporting System database

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system

Memantine induces manic episode in a 73-year-old patient with vascular neurocognitive disorder: a case report.

Data mining techniques for detecting signals of adverse drug reaction of cardiac therapy drugs based on Jinan adverse event reporting system database: a retrospective study

Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database

Mining and analysis of adverse drug reactions associated with perampanel based on FAERS database

Effects of Memantine on Clinical Ratings, Fluorodeoxyglucose Positron Emission Tomography Measurements, and Cerebrospinal Fluid Assays in Patients with Moderate to Severe Alzheimer Dementia A 24-Week, Randomized, Clinical Trial

Multicenter Research on Efficacy and Tolerance of Memantine in Chinese Patients with Alzheimer's Disease

Mining of neurological adverse events associated with valbenazine: A post-marketing analysis based on FDA adverse event reporting system

Memantine Treatment in Alzheimer Disease: a Randomized Double-Blind Controlled Trial

[Analysis of adverse reactions risk signal of Xinyuan Capsules based on national ADR monitoring spontaneous reporting system]

Analysis of lumateperone data for patients with schizophrenia using related adverse events from the FDA adverse reporting system

Data mining and safety analysis of dual orexin receptor antagonists (DORAs): a real-world pharmacovigilance study based on the FAERS database

Combining a Pharmacological Network Model with a Bayesian Signal Detection Algorithm to Improve the Detection of Adverse Drug Events

Dexmedetomidine: a real-world safety analysis based on FDA adverse event reporting system database

A real-world pharmacovigilance study of esketamine nasal spray

Signal detection of nervous system from Shanghai spontaneous ADR reporting system reports